Gene Logic, Abbott strike development deal

Gene Logic has inked a deal with Abbott to study new pathways for a group of experimental therapies that have passed Phase I. The deal gives Gene Logic a schedule of milestone payments for any successful new programs. Gene Logic's Drug Repositioning Program seeks to find alternative indications for drug candidates with good safety records that have been de-prioritized or discontinued in clinical trials. This is the fifth alliance with Big Pharma by Gene Logic.

- see this release on the pact

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.